Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
They hit their mark at ASCO for 667 & ava:

Good results at EHA for mastocytosis with ava:

Conference call from EHA:

-announced NDA for ava for 4th line GIST as well as GIST with specific mutations.

This company promised all of these on their timeline, and has delivered. Plus there is the Array buyout, and with folks wondering who's next, BPMC makes sense, plus potential future approvals for ava (3rd line for GIST in 2020, advanced systemic mastocytosis in 1H 2020), and an NDA for 667 (RET fusion NSCLC in 2020).
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.